Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jessica Niswonger"'
Autor:
Julie O'Neal, Matthew L. Cooper, Julie K. Ritchey, Susan Gladney, Jessica Niswonger, L. Sofía González, Emily Street, Gabriel J. Haas, Alun Carter, Parmeshwar N. Amayta, Feng Gao, Byung Ha Lee, Donghoon Choi, Melissa Berrien-Elliott, Alice Zhou, Todd A. Fehniger, Mike P. Rettig, John F. DiPersio
Publikováno v:
Journal of Bone Oncology, Vol 45, Iss , Pp 100537- (2024)
Externí odkaz:
https://doaj.org/article/b38c06c8aead4dca8c8f9a443a0143a0
Autor:
Julie O’Neal, Julie K. Ritchey, Matthew L. Cooper, Jessica Niswonger, L. Sofía González, Emily Street, Michael P. Rettig, Susan W. Gladney, Leah Gehrs, Ramzi Abboud, Julie L. Prior, Gabriel J. Haas, Reyka G. Jayasinghe, Li Ding, Armin Ghobadi, Ravi Vij, John F. DiPersio
Publikováno v:
Leukemia. 36(6)
Despite improvement in treatment options for myeloma patients, including targeted immunotherapies, multiple myeloma remains a mostly incurable malignancy. High CS1 (SLAMF7) expression on myeloma cells and limited expression on normal cells makes it a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cfb5f18588f85274eef94aca5132224
https://pubmed.ncbi.nlm.nih.gov/35422095
https://pubmed.ncbi.nlm.nih.gov/35422095
Autor:
John F. DiPersio, Jessica Niswonger, Julie Ritchey, Bader Alahmari, Matthew L. Cooper, Samuel Achilefu, Karl Staser, Kiran Vij, Lynne Marsala, Kidist Ashami, Ikuo Tsunoda, Jaebok Choi, Bing Wang, Mark A. Schroeder
Publikováno v:
Leukemia
The therapeutic benefits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) are derived from the graft-versus-leukemia (GvL) effects of the procedure. There is a strong association between the GvL effects and graft-versus-host disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffe8dfd9b2606e59d652ad37a0de214a
https://doi.org/10.1038/s41375-018-0123-z
https://doi.org/10.1038/s41375-018-0123-z
Autor:
Matthew L. Cooper, Jonathan A. Pachter, John F. DiPersio, Alun Carter, Parmeshwar Amatya, Jessica Niswonger, Julie Ritchey
Publikováno v:
Blood. 136:1-2
Despite remarkable clinical efficacy, CAR-T therapy has been limited by life-threatening toxicities in over 30% of patients (Maude, NEJM 2014 and Davila, SciTransMed 2014). Toxicities primarily manifest as Cytokine Release Syndrome (CRS) characterize
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::464a2abe66578e3f1994be2a1ffec79a
https://doi.org/10.1182/blood-2020-139904
https://doi.org/10.1182/blood-2020-139904
Autor:
Sofia Gonzalez, Julie O'Neal, Jessica Niswonger, John F. DiPersio, Armin Ghobadi, Matthew L. Cooper, Miriam Y. Kim, Julie Ritchey
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e166-e167
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9103c6be5254b7c9a7b6b55403fe97bd
https://doi.org/10.1016/j.clml.2019.09.278
https://doi.org/10.1016/j.clml.2019.09.278
Autor:
Julie O'Neal, Armin Ghobadi, Miriam Y. Kim, Matthew L. Cooper, John F. DiPersio, Julie Ritchey, Jessica Niswonger
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:S382-S383
Outcomes for myeloma patients have improved, however, most patients suffer fatal relapse. Although CD19 CAR-Ts for B cell malignancies have attained cure, BCMA CAR-T treatment results in 30-70% complete responses but responses are often not durable.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87bacc9a7037aa9a82eebc52a98a0dee
https://doi.org/10.1016/j.bbmt.2018.12.623
https://doi.org/10.1016/j.bbmt.2018.12.623
Autor:
Byung Ha Lee, Julie O'Neal, Jessica Niswonger, Jaehan Park, Julie Ritchey, Donghoon Choi, John F. DiPersio, Matthew L. Cooper, Sofia Gonzalez
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 19:e25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::493b0f3bb6d99ac6a5db46ac0a85a8ce
https://doi.org/10.1016/j.clml.2019.09.037
https://doi.org/10.1016/j.clml.2019.09.037
Autor:
Elisa De Togni, Julie Ritchey, Jessica Niswonger, Matthew L. Cooper, John F. DiPersio, Julie O'Neal, Miriam Y. Kim
Publikováno v:
Blood. 132:2205-2205
Chimeric antigen receptor (CAR) T cells are a novel therapeutic approach which have shown good clinical outcomes in patients receiving CD19 CAR T cells for B cell acute lymphoblastic leukemia. CAR T cells are made to express a CAR that recognizes a s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c080d80684f753800c85c01f062ad45
https://doi.org/10.1182/blood-2018-99-113438
https://doi.org/10.1182/blood-2018-99-113438
Autor:
Amanda F. Cashen, Amy Musiek, Anand Chukka, Kidist Ashami, Byung Ha Lee, Jaebok Choi, Jaehan Park, Karl Staser, Shunqiang Li, John F. DiPersio, Matthew L. Cooper, Jessica Niswonger
Publikováno v:
Blood. 132:340-340
Background: Sézary syndrome (SS) is a highly-morbid T cell leukemic lymphoma with no widely-effective treatments and few preclinical models. We demonstrated effective T cell lymphoma therapy with allogeneic gene-edited anti-CD7 CARTs (Cooper et al,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c691e2feae3114da14ba675e08dd3c1f
https://doi.org/10.1182/blood-2018-99-119375
https://doi.org/10.1182/blood-2018-99-119375
Autor:
Julie Ritchey, Jaehan Park, Byung Ha Lee, Jessica Niswonger, Matthew L. Cooper, John F. DiPersio, Karl Staser
Publikováno v:
Blood. 132:2199-2199
Background: Chimeric antigen receptor T cell (CART) therapy is revolutionizing modern cancer therapy, with two anti-CD19 CARTs FDA-approved for relapsed/refractory B cell lymphoma/leukemia and many other CARTs for solid and liquid tumors currently un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::301c8b4113464c7c52d48fcc9ce57cfc
https://doi.org/10.1182/blood-2018-99-117265
https://doi.org/10.1182/blood-2018-99-117265